Nivolumab-induced thyroid dysfunction

Japanese Journal of Clinical Oncology

Volumn 46, Issue 6, 2016, Pages 575-579

  Tanaka, Ryota ^a   Fujisawa, Yasuhiro ^a   Maruyama, Hiroshi ^a   Nakamura, Yasuhiro ^b   Yoshino, Koji ^c   Ohtsuka, Mikio ^d   Fujimoto, Manabu ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Endocrine med; Immunotherapy; Skin

Indexed keywords

DACARBAZINE; LIOTHYRONINE; NIVOLUMAB; PREDNISOLONE; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE MYOSITIS; CASE REPORT; COLOR DOPPLER FLOWMETRY; DRUG WITHDRAWAL; ECHOGRAPHY; FATIGUE; FEMALE; FEVER; HASHIMOTO DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MALE; MELANOMA; MIDDLE AGED; MUCOSAL MELANOMA; MYALGIA; MYOSITIS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SUBCLINICAL HYPOTHYROIDISM; THYROID DISEASE; THYROIDITIS; VAGINA TUMOR; VAGINAL MELANOMA; VERY ELDERLY; QUALITY OF LIFE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOTHYROIDISM; MALE; MELANOMA; MIDDLE AGED; QUALITY OF LIFE; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 84991830062     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyw036     Document Type: Article

References (21)

1. Giraldo NA, Becht E, Vano Y, Sautes-Fridman C, Fridman WH. The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Arch 2015;467:127-35.
2. Postow M, Callahan MK, Wolchok JD. Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J 2011;17: 372-8.
3. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008;224:166-82.
4. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.
5. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011;11:805-12.
6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366: 2443-54.
7. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30.
8. Maverakis E, Cornelius LA, Bowen GM, et al. Metastatic melanoma-a review of current and future treatment options. Acta Derm Venereol 2015;95:516-24.
9. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrinerelated adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014;21:371-81.
10. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. New Engl J Med 2015;372:320-30.
11. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010;37:499-507.
12. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53.
13. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-9.
14. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23: 741-50.
15. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-8.
16. Hasham A, Tomer Y. Genetic and epigenetic mechanisms in thyroid autoimmunity. Immunol Res 2012;54:204-13.
17. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013;98:1361-75.
18. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363: 711-23.
19. Deeks ED. Nivolumab: a review of its use in patients with malignant melanoma. Drugs 2014;74:1233-9.
20. Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet 2012;379:1155-66.
21. Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011;21:593-646.